Financial Analysis: TherapeuticsMD (TXMD) & Its Rivals
TherapeuticsMD (NASDAQ: TXMD) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its rivals? We will compare TherapeuticsMD to similar companies based on the strength of its risk, analyst recommendations, valuation, earnings, profitability, dividends and institutional ownership.
This table compares TherapeuticsMD and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares TherapeuticsMD and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|TherapeuticsMD||$19.36 million||-$89.87 million||-14.62|
|TherapeuticsMD Competitors||$3.02 billion||$642.98 million||-30.13|
TherapeuticsMD’s rivals have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional & Insider Ownership
76.8% of TherapeuticsMD shares are held by institutional investors. Comparatively, 64.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 23.9% of TherapeuticsMD shares are held by company insiders. Comparatively, 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility and Risk
TherapeuticsMD has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, TherapeuticsMD’s rivals have a beta of 1.24, indicating that their average stock price is 24% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for TherapeuticsMD and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD currently has a consensus price target of $14.72, suggesting a potential upside of 151.66%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 20.33%. Given TherapeuticsMD’s stronger consensus rating and higher probable upside, research analysts plainly believe TherapeuticsMD is more favorable than its rivals.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
Receive News & Stock Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related stocks with our FREE daily email newsletter.